Dr.Datsons Labs Ltd.
|BSE: 533412||Sector: Health care|
|NSE: DRDATSONS||ISIN Code: INE928K01013|
|BSE 00:00 | 04 Mar||Dr.Datsons Labs Ltd|
|NSE 05:30 | 01 Jan||Dr.Datsons Labs Ltd|
Dr.Datsons Labs Ltd. (DRDATSONS) - News Sector
5.20 pm | 19 May 2022 | Business Standard
The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.
2.50 pm | 19 May 2022 | Business Standard
Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review
9.39 am | 19 May 2022 | Business Standard
Lupin's performance was skewed on revenues front amid US and India posting lower than expected sales while RoW and South Africa saw better than antici...
9.35 pm | 18 May 2022 | Business Standard
The struggle that he went through in setting up a private health care facility in the India of the 1980s is part of folklore
9.25 pm | 18 May 2022 | Business Standard
Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country
9.22 pm | 18 May 2022 | Business Standard
'Cipla has so many capabilities that for anything we need to do, we say we can do it'
9.18 pm | 18 May 2022 | Business Standard
Having consolidated its presence across geographies, the pharma major is looking at acquisitions
3.16 pm | 18 May 2022 | Business Standard
The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.
9.52 am | 18 May 2022 | Business Standard
In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 p...
1.47 am | 18 May 2022 | Business Standard
Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line
12.42 pm | 17 May 2022 | Business Standard
Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 q...
1.05 am | 17 May 2022 | Press Trust of India
Revenue from operations rose to Rs 810 crore for the fourth quarter, compared with Rs 744 crore in the year-ago period, the pharmaceutical major said ...
3.01 am | 16 May 2022 | Business Standard
The last two years saw limited physical inspections due to travel restrictions during the pandemic
12.04 am | 14 May 2022 | Business Standard
Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statin...
2.03 am | 12 May 2022 | Business Standard
Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the co...
11.46 pm | 11 May 2022 | Business Standard
The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said
12.27 pm | 11 May 2022 | Business Standard
In Q4FY22, Ajanta's earnings before interest, taxes, depreciation, and amortization declined 20 per cent year-on- year to Rs 207 crore.
8.11 am | 11 May 2022 | Business Standard
Stocks to Watch Today: The primary market too is likely to be abuzz with activity with three IPOs namely - Delhivery, Prudent Corporate Advisory Servi...
2.26 am | 11 May 2022 | Business Standard
For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively
1.22 am | 11 May 2022 | Business Standard
Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days